Theolytics doses first patient in Phase I/IIa Trial of THEO-260 in ovarian cancer
19 November 2024
Ovarian Cancer is one of the leading causes of cancer related deaths among women. Theolytics’ discovery platform was applied to identify a mechanistically differentiated adenovirus - THEO-260 - for high grade serous ovarian cancer.
OMass Therapeutics appoints Professor Steven Charlton as Chief Scientific Officer
15 November 2024
Professor Charlton, who joined OMass in 2020 as Vice President of Pharmacology, succeeds Dr. Ali Jazayeri, who is leaving the company to pursue other opportunities.
CyanoCapture at the Forefront: H2Boost deployment and COSEC Horizon grant to scale biogenic CO2 capture
10 November 2024
CyanoCapture is making significant strides in advancing sustainable carbon capture technologies with its involvement in two major projects. Both initiatives highlight CyanoCapture's commitment to pioneering carbon-negative solutions and driving progress toward a sustainable, low-carbon future.
Infinitopes to showcase breakthroughs on cancer vaccine development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial
8 November 2024
Infinitopes announced that it will be presenting three posters on its cancer vaccine discovery and development, including one that has been recognised as a ‘top 100’ poster presentation, at the Society for Immunotherapy of Cancer (SITC) 2024, held in Houston, US, from 6-10th November.
Leading academics and innovators join refreshed BioEscalator Management Board
30 October 2024
In its first major refresh since its establishment in 2018, the BioEscalator is delighted to welcome four leading University of Oxford academics and innovators to its Management Board. Professors Catherine Green OBE, Beth Psaila, Molly Stevens DBE and Krina Zondervan are joining alongside a fifth new member, Peter Callow, Financial Controller of the Medical Sciences Division at the University of Oxford. The Management Board provides a source of expertise for BioEscalator tenants and works to enhance research at the University by building strong links with small life sciences companies.
Nucleome Therapeutics announces a strategic collaboration with Johnson & Johnson* to map genetic associations linked to autoimmune disease
21 October 2024
Nucleome Therapeutics will combine its proprietary machine learning and high-resolution 3D genomics technologies in combination with Johnson & Johnson's immunology and data science capabilities to discover new target genes and the cell types that drive autoimmune diseases, which could facilitate the classification of patients most likely to respond to therapy.
Internationally renowned academic Lee Sweetlove joins Moa
15 October 2024
Oxford University Professor to work on advanced understanding of Moa's novel modes of action.
Moa’s ground breaking science features in journal Weed Science
9 October 2024
Breaking the 30 year impasse in novel herbicide discovery.
A plant sciences spin-out flourishes at the BioEscalator
2 October 2024
BioEscalator news Company insights
‘Mighty oaks from little acorns grow.’ And so it is with novel herbicide developer Moa Technology, which has grown from four people when it first became a BioEscalator tenant to a company of 85 with research facilities in Oxford and Yorkshire.
Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®
2 October 2024
Enara will use the money raised to advance its pipeline of TCR-based immunotherapies against novel and differentiated Dark Antigen targets for solid tumours.
OMass Therapeutics expands development team with key appointments in US and UK and announces the nomination of clinical candidate against MC2
30 September 2024
Over the last year, OMass has reportedly made significant process in advancing its pipeline and has selected its first clinical candidate targeting the MC2 receptor, a GPCR for the adrenocorticotropic hormone (ACTH).
Moa and Biomar announce bio-herbicide collaboration
16 September 2024
Moa has entered into a long-term collaboration with Biomar Microbial Technologies to strengthen its bio-herbicide and development programme.
Alchemab appoints Co-Founder Jane Osbourn as Chief Executive Officer
11 September 2024
As Co-Founder and CSO, Jane has led all aspects of Alchemab’s platform development and drug discovery activities to date and brings to the CEO role more than 30 years of biopharmaceutical industry experience.
CardiaTec secures $6.5M seed funding to advance its multi-omics drug discovery platform for cardiovascular diseases
9 September 2024
The new funds will allow CardiaTec to expand its platform and progress proprietary drug targets to wet lab validation.
Eterna Biologics: Revolutionising RNA therapeutics
28 August 2024
We are excited to welcome Eterna Biologics, a University of Oxford biotech spinout company with a mission to unleash the full potential of RNA medicines. The company aims to enhance global health by expanding the applicability of RNA-targeting medicine to develop treatment for a wide range of human conditions.
Evolvere Biosciences accepted into the prestigious Y Combinator program
23 August 2024
The team of University of Oxford students is making strides that could transform our approach to antibiotics.
U-Ploid thrilled to join the BioEscalator Community
21 August 2024
U-Ploid Biotechnologies joins the BioEscalator to develop groundbreaking therapeutics that improve egg quality and revolutionise IVF.
Moa announces international field trial success at the ACS autumn conference in Denver
19 August 2024
Oxford University spin-out Moa Technology has announced excellent results in multi-country field trials of promising new classes of herbicide with novel modes of action recently discovered by the company.
CyanoCapture continues to make strides in the green sciences industry
11 August 2024
CyanoCapture was selected as one of the two winners of the Green Sciences Incubator challenge, which L'Oréal organised in collaboration with Genopole and Hello Tomorrow.
RE-AIM Therapeutics: Targeting disease causal cells to cure autoimmunity
18 July 2024
We are delighted to welcome RE-AIM Therapeutics to the BioEscalator community, a start-up focused on developing antibody-based curative therapies for inflammatory disorders, such as psoriasis and inflammatory bowel disease.